NIA-AA Symposium: Enabling Precision Medicine for Alzheimer’s Disease Through Open Science

July 28-29, 2022
Marriott Marquis San Diego Marina, Marina Ballroom D
All times are in Pacific Time (North America)
In-person attendance only

Overview
The 5th Annual NIA-AA Symposium on Enabling Precision Medicine for Alzheimer’s Disease Through Open Science will feature an array of NIA-supported translational research programs that employ precision medicine principles and open-science practices to: 1. Understand the complex and heterogeneous etiology of Alzheimer’s including mechanisms of neuropsychiatric symptoms in AD/ADRD; 2. Identify and validate new disease-relevant targets and biomarkers; 3. Develop the next generation animal models for late-onset AD; 4. Advance novel targets into drug discovery. The symposium program will feature speakers from the Accelerating Medicines Partnership® for Alzheimer’s (AMP® AD) and its affiliated systems biology consortia, the MODEL-AD and TREAT-AD translational centers, and other precision medicine research programs.

Symposium Organizers
- Suzana Petanceska, National Institutes of Health
- Larry Refolo, National Institutes of Health
- Laurie Ryan, National Institutes of Health
- Erika Tarver, National Institutes of Health

Target Audience
Academic, biotech and pharmaceutical industry researchers with interest in target and biomarker discovery and preclinical and clinical drug development; computational biologists; data scientists; and open science advocates.

Registration
Preconferences are offered for in-person attendance only. Preconferences require a separate registration in addition to AAIC full conference registration, or you may register for them as stand-alone events.

Register today for NIA-AA Symposium: Enabling Precision Medicine for Alzheimer’s Disease Through Open Science.
Agenda

**Day One: July 28**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 – 1:15 p.m.</td>
<td>Welcome and Introductions</td>
</tr>
<tr>
<td>1:15 – 3:30 p.m.</td>
<td>Session 1: AMP AD – Deconstructing Disease Complexity through Multi-omic Mapping of Brain, CSF, and Blood</td>
</tr>
<tr>
<td>3:30 – 3:45 p.m.</td>
<td>Coffee Break</td>
</tr>
<tr>
<td>3:45 – 6 p.m.</td>
<td>Session 2: Understanding the Mechanisms of the Neuropsychiatric Symptoms in AD</td>
</tr>
</tbody>
</table>

**Day Two: July 29**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>8 – 8:15 a.m.</td>
<td>Welcome</td>
</tr>
<tr>
<td>8:15 – 10 a.m.</td>
<td>Session 3: Enabling Precision Medicine Approach to AD Treatment and Prevention: From Cohort Studies to Clinical Trials</td>
</tr>
<tr>
<td>10 – 10:30 a.m.</td>
<td>Break</td>
</tr>
<tr>
<td>10:30 a.m. – 12:30 p.m.</td>
<td>Session 4: Enabling Data Infrastructure, Tools and Methods for the Discovery of Novel Targets and Biomarkers and for Advancing Drug Repurposing</td>
</tr>
<tr>
<td>12:30 – 1:30 p.m.</td>
<td>Lunch</td>
</tr>
<tr>
<td>1:30 – 3:30 p.m.</td>
<td>Session 5: MODEL-AD Consortium – Developing New Mouse Models of LOAD to Enable a Precision Medicine Approach to Preclinical Drug Development</td>
</tr>
<tr>
<td>3:30 – 4 p.m.</td>
<td>Break</td>
</tr>
<tr>
<td>4 – 6 p.m.</td>
<td>Session 6: TREAT-AD Centers – Expanding the Target Landscape for AD and Accelerating Drug Discovery for Novel Targets</td>
</tr>
</tbody>
</table>

**Speakers**

- Matthias Arnold, Helmholtz University/Duke University
- Alison Axtman, University of North Carolina
- Priyanka Baloni, Institute for Systems Biology
- Greg Carter, The Jackson Laboratory
- Al Edwards, Structural Genomics Consortium, University of Toronto
- Nilüfer Ertekin-Taner, Mayo Clinic
- Kim Green, University of California, Irvine
Anna Greenwood, Sage Bionetworks
Laura Heath, Sage Bionetworks
Edward Huey, Columbia University
Rima Kaddurah Daouk, Duke University
Amy Kind, University of Wisconsin-Madison
Jan Krumsiek, Cornell University
Ed Lein, Allen Institute for Brain Science
Katie Lunnon, Exeter University
Vilas Menon, Columbia University
Lisa Nickerson, Harvard University
Sid O’Bryant, University of North Texas Health Science Center
Adrian Oblak, Indiana University
Alan Palkowitz, Indiana University
Michael Rafii, University of Southern California
Rema Raman, University of Southern California
Ben Readhead, Arizona State University
Tim Richardson, Indiana University
Monica Rivera-Mindt, Fordham University and Icahn School of Medicine
Stacey Rizzo, University of Pittsburgh
Panos Roussos, Icahn School of Medicine
Andrew Saykin, Indiana University
Vivek Swarup, University of California, Irvine
Paul Territo, Indiana University
Paul Thompson, University of Southern California
Aliza Wingo, Emory University
Jie Zhang, Indiana University